A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Mineral Density, Bone Metabolism, Radiographically-detected Osteolytic Bone Lesions, Skeletal-related Events and Bone Pain in Multiple Myeloma Patients at First Relapse - Not available

Prof. M.A. Dimopoulos0 sitesStarted: October 20, 2009Last updated: August 5, 2013

Drugs

Trial Snapshot

Phase: Not Applicable
Status: Active, not recruiting
Sponsor

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional clinical trial of medicinal product

Eligibility Criteria

Sex: All

Inclusion Criteria

•Subjects must satisfy all the following criteria to be enrolled in the study:
•myeloma patients at first relapse
•age = 18 years
•?arnofsky performance status = 60 (patients with lower performance status due to myeloma bone disease can also be included)
•measurable disease
•platelet count >50x109/L
•neutrophil count >0.75x109/L
•hemoglobin =7.0 g/dL (the use of recombinant human erythropoietin or red blood cell transfusions to maintain hemoglobin levels above 7.0 g/dL is not an exclusion criterion)
•serum ALT and AST = 3-fold of upper normal limit
•serum bilirubin = 2-fold of upper normal limit
•serum Calcium = 10.5 mg/dL
•expected survival = 2 months
•signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Potential subjects who meet any of the following criteria will be excluded from participating in the study:
•presence of another cancer
•serious medical or psychiatric illness likely to interfere with participation in this clinical study
•grade 2-4 peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3
•pregnant women or breast-feeding
•women of childbearing potential not using adequate contraception
•known or suspected hypersensitivity or intolerance to bortezomib, boron, mannitol, zoledronic acid, dexamethasone, or heparin (if an indwelling catheter is used)
•uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months prior to first dose of study drug)
•uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 4, NYHA Classification of Cardiac Disease), uncontrolled angina, pericardial disease, or cardiac amyloidosis
•acute diffuse infiltrative pulmonary disease
•history of hypotension or patient has decreased blood pressure (sitting systolic blood pressure [SBP] £100 mmHg and/or sitting diastolic blood pressure [DBP] £60 mmHg)
•patient has received extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks prior to enrolment
•patient has received any drugs or agents that inhibit (e.g., cimetidine, erythromycin, fluoxetine, ketoconazole, paroxetine) or induce (e.g., carbamazepine, glucocorticoids, phenobarbital, rifampin) CYP2C19 or CYP3A4 within 14 days before the first dose of VELCADE (proton pump inhibitors are allowed)
•need for therapy with concomitant CYP 3A4 inhibitors (e.g., itraconazole, fluconazole, clarithromycin, erythromycin, norfloxacin, fluvoxamine, cimetidine, indinavir, ritonavir) or inducers (e.g., efavirenz, barbiturates, phenytoin, rifampin, glitazones). Proton pump inhibitors are allowed.
•Patient has received an experimental drug or has used an experimental medical device within 4 weeks prior to the planned start of treatment. Concurrent participation in non-treatment studies is allowed, provided it will not interfere with participation in this study.

Investigators

Sponsor

Prof. M.A. Dimopoulos

Similar Trials

Active, not recruiting

Phase 1

Study to evaluate Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple Myeloma who Have Received at least 2 Prior Lines of Therapy including Lenalidomide and a Proteasome Inhibitor

EUCTR2017-003951-44-GRHellenic Society of Hematology57

Recruiting

Phase 4

Clinical trial on replacement of damaged skin in patients

CTRI/2020/02/023205ifeNet Health Inc

Active, not recruiting

Not Applicable

A 12-month research project for children who have gone through the FUTURE 5 research project and who want to continue treatment to see how well bosentan is tolerated when administered over a long period of time.Pulmonary arterial hypertension (PAH) in childrenMedDRA version: 14.1Level: LLTClassification code 10064908Term: Associated with (APAH)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.1Level: LLTClassification code 10064909Term: Idiopathic (IPAH)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.1Level: LLTClassification code 10064910Term: Familial (FPAH)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

EUCTR2011-004612-31-PTActelion pharmaceuticals Ltd105

Active, not recruiting

Phase 1

EUCTR2011-004612-31-NLActelion pharmaceuticals Ltd105

Active, not recruiting

Phase 1

EUCTR2011-004612-31-FRActelion pharmaceuticals Ltd105